Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for treating atherosclerosis and a preparation method thereof

a technology of atherosclerosis and composition, which is applied in the field of composition, can solve the problems of renal hypertension and even uremia, side effects of stomach upset, diarrhea or constipation, etc., and achieve the effect of increasing the expression of ppar

Inactive Publication Date: 2013-02-14
KAOHSIUNG MEDICAL UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a substance that increases the amount of a protein called PPARγ. This substance can be translated from a specific type of RNA. The technical effect of this is that it helps to increase the amount of PPARγ in the body, which can have beneficial effects on certain medical conditions.

Problems solved by technology

The occurrence of cerebral or carotid arteriosclerosis will result in renal hypertension and even uremia.
However, the side effect of stomach upset (diarrhea or constipation) might occur.
Nevertheless, the side effects such as stomach upset, hyperuricacidemia, gout, exanthema and the upgrade of liver function indexes and so on would occur.
Its chemical structure is similar to that of vitamin K, and its functional mechanism is to counteract the activity responses of vitamin K-dependent coagulation factors II, VII, IV and X. However, Vitamin K antagonist will result in the side effects such as hematuria, gastrointestinal bleeding, intracerebral hemorrhage and so on.
However, heparin might generate the side effects such as bleeding, hypersensitivity, platelet deficiency disease and so on.
Although hirudin is the most effective natural anticoagulant, it is difficult to extract it from leeches and hirudin must be prepared with the recombinant biotechnology.
Since aspirin will reduce the secretion of protection materials in stomach, so that side effects, e.g. stomach upset, gastrointestinal bleeding and so on, would occur.
Among ADP receptor inhibitors, Clopidogrel would have the risk of stomach bleeding.
Thus, Cilostazol has the functions of anti-platelet aggregation and angiectasis, but results in side effects such as headache, diarrhea, vomit, erythematous rash, and hematological abnormality, etc.
When dipyridamole is administered with heparin, bleeding risk would be increased.
Among thromboxane inhibitors, Terutroban can block platelet aggregation and vasoconstriction induced by thromboxane, promote endoderm's functions and has anti-atherosclerosis effect, whereas it also has the bleeding risk.
Thrombolytic agent is suitable for treating deep vein thrombosis, pulmonary embolism, acute myocardial infarction and acute arterial embolism, but it will result in bleeding and hypersensitivity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating atherosclerosis and a preparation method thereof
  • Composition for treating atherosclerosis and a preparation method thereof
  • Composition for treating atherosclerosis and a preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

embodiments

Experiment 1

Preparation of Chalcone Compounds

[0037]

[0038]Chalcone compound has ring A and ring B. For ease of illustration, the denotations of carbon atoms on ring A and ring B are shown as above.

[0039]The synthesis of the chalcone compounds in the present invention was carried out by a Claisen-Schmidt condensation. Taking chalcone compound 1 as the example, a mixture of 2-hydroxyacetophenone (273.6 mg, 2.01 mmol), 4-methoxybenzaldehyde (279.1 mg, 2.05 mmol), potassium hydroxide (KOH, 50% w / v, 2 ml) and ethanol (100% v / v, 20 ml) was stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure and then partitioned with ethyl acetate (EtOAc) and H2O. The organic layer was then evaporated, and the residue was purified using column chromatography (silica gel: 70-230, Merck; n-hexane-EtOAc, 15:1, Rf=0.2) to give 2-hydroxy-4′-methoxychalcone (chalcone compound 1, 273.6 mg; yield, 53.6%). The purity of compound 1 was greater than 95%, which was det...

experiment 2

Activity of Chalcone Compound 1 and Other Flavonoid Compounds on Inhibiting HASMCs Proliferation

[0041]The skeleton of flavonoid compound is constructed by C6-C3-C6, and chalcone also belongs to this genus of structure. Generally speaking, the representative active flavonoid can be divided as six groups, including flavonol, flavanone, flavan-3-ol, flavone, isoflavone and anthocyanin. Followings are the basic skeleton in each genus of flavonoid compounds and the examples used in the present invention.

[0042]For analyzing whether each genus of flavonoid compounds could inhibit the activity of HASMCs proliferation, the proliferation and cell viability of HASMCs were determined using WST-1 reagent (Roche Applied Science, Penzberg, Germany). WST-1 is a tetrazolium salt that will be cleaved to formazan by mitochondrial dehydrogenases in viable cells. First, HASMCs were seeded into 96-well plates. After the density reaching 70% confluence, the cells were “synchronized” for 24 hours by replac...

experiment 3

Anti-Proliferation Effect of Compound 1 on HASMCs Stimulated with Ox-LDL

[0045]Please refer to FIG. 2, Ox-LDL (30 μg / ml) increased cell proliferation about 50% in HASMCs. As compared to Ox-LDL treatment group, cell proliferation of compound 1 treatment (1, 2.5 and 5 μg / ml) significantly decreased in a dose dependent manner.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Compositionaaaaaaaaaa
Therapeuticaaaaaaaaaa
Login to View More

Abstract

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44 / 42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).

Description

CROSS-REFERENCE TO RELATED APPLICATION AND CLAIM OF PRIORITY[0001]The application claims the benefit of Taiwan Patent Application No. 100128614, filed on Aug. 10, 2011, in the Taiwan Intellectual Property Office, the disclosures of which are incorporated herein in their entirety by reference.FIELD OF THE INVENTION[0002]The present invention relates to a chalcone composition and the preparation method thereof. In particular, the present invention relates to a composition for preventing and treating atherosclerosis and the preparation method thereof.BACKGROUND OF THE INVENTION[0003]Cardiovascular disease is a symptom of heart and blood vessels. Cardiovascular disease can be grouped as coronary artery heart disease, cerebrovascular disease, peripheral arterial occlusion disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary embolism. Ischemic heart disease, myocardial infarction or sudden death will be induced if coronary arteriosclerosis occurs....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/12C07C49/835A61K31/353A61K31/4439A61P9/10C07C49/84A61P29/00
CPCA61K31/4439C07C49/835C07C49/84A61K31/122A61K31/352A61K31/12A61K45/06A61K2300/00A61P9/10A61P29/00
Inventor WU, YANG-CHANGCHANG, FANG-RONGHSIEH, TUSTY-JIUANJUO, SUH-HANGLIN, AN-SHENDU, YING-CHI
Owner KAOHSIUNG MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products